DMRA
Damora Therapeutics, Inc.Company Information
- Company Name
- Damora Therapeutics, Inc.
- CIK
- CIK0001800315
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- DMRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DMRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-25
- Last sale
- 2026-07-06
- Shares purchased (TTM)
- 12,500
- Shares sold (TTM)
- 1,335
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 64,519,354
- Shares outstanding
- 61,117,057
- Ownership
- 105.57%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 1.76%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 541 | 533 | 258 | 8 | 10 | 12 | 14 | 20 | 23 | 21 | 21 | 23 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | - | - | 6 | 12 | 21 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 3 | ||||||
| Assets Current | 544 | 535 | 260 | 10 | 13 | 15 | 17 | 21 | 25 | 31 | 37 | 47 | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 2 | 1 | 2 | ||||||
| Assets | 544 | 535 | 261 | 11 | 14 | 15 | 17 | 23 | 27 | 32 | 38 | 50 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 9 | 6 | 2 | 2 | 2 | 1 | 1 | 2 | 3 | 3 | 4 | 8 | ||||||
| Option Contract Indexed To Equity Settlement Share Fair Value | 10 | 5 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 28 | 24 | 20 | 3 | 3 | 2 | 1 | 2 | 4 | 4 | 6 | 13 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Liabilities | 28 | 24 | 20 | 3 | 3 | 2 | 1 | 2 | 4 | 4 | 6 | 13 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Additional Paid In Capital | 932 | 894 | 311 | 292 | 292 | 292 | 292 | 291 | 290 | 289 | 288 | 287 | ||||||
| Retained Earnings Accumulated Deficit | -546 | -515 | -487 | -287 | -283 | -280 | -278 | -271 | -267 | -262 | -256 | -250 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | 516 | 512 | 240 | 8 | 11 | 14 | 16 | 21 | 24 | 28 | 32 | 37 | ||||||
| Liabilities And Stockholders Equity | 544 | 535 | 261 | 11 | 14 | 15 | 17 | 23 | 27 | 32 | 38 | 50 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Series B Non Voting Convertible Preferred Stock | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Series C Non Voting Convertible Preferred Stock | -0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Temporary Equity Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | 10 | - | ||||||
| Temporary Equity Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | - | - | - | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 300 | 300 | 300 | 500 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 62 | 60 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 62 | 60 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDamora Therapeutics, Inc. (DMRA) — SEC Financial Statements & Analysis
Damora Therapeutics, Inc. (DMRA) is a pharmaceutical preparations company, incorporated in DE. Damora Therapeutics, Inc. trades on Nasdaq as: DMRA. Damora Therapeutics, Inc. (DMRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Damora Therapeutics, Inc. carries a market cap of $1.59B, a P/E ratio of -6.05x, a P/B ratio of 3.08x, an enterprise value of $1.05B, and an EV/EBITDA multiple of -3.88x. On profitability, it posts a Return on Equity (ROE) of -99.74%, a Return on Assets (ROA) of -94.32%, and a Return on Invested Capital (ROIC) of -2976.03%. Per share, it reports EPS of $-4.30, diluted EPS of $-4.30, free cash flow per share of $-0.73, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 1483.86% year-over-year and EPS growth of -65.73% year-over-year. On the balance sheet, it maintains a current ratio of 19.73x, a quick ratio of 19.62x, working capital of $516.04M, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, an interest coverage ratio of -33.12x, free cash flow of $-44.52M (TTM), and net debt of $-540.51M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.59B
- P/E TTM
- -6.05x
- EPS TTM
- $-4.30
- P/B TTM
- 3.08x
- ROE TTM
- -99.74%
- ROA TTM
- -94.32%
- Debt To Equity
- 0.05x
- Free Cash Flow TTM
- $-44.52M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Damora Therapeutics, Inc. in?
Damora Therapeutics, Inc. (DMRA) operates in the Pharmaceutical Preparations industry.
What exchange does DMRA trade on?
Damora Therapeutics, Inc. (DMRA) trades on the Nasdaq.
Where is Damora Therapeutics, Inc. incorporated?
Damora Therapeutics, Inc. is incorporated in DE.
When was Damora Therapeutics, Inc. (DMRA)'s most recent SEC filing?
Damora Therapeutics, Inc. (DMRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is DMRA's market cap?
Damora Therapeutics, Inc. (DMRA) has a market capitalization of $1.59B as of 2026-06-30.
What is DMRA's EPS (earnings per share)?
Damora Therapeutics, Inc. (DMRA)'s trailing twelve month EPS is $-4.30 as of 2026-06-30.
What is DMRA's ROE (return on equity)?
Damora Therapeutics, Inc. (DMRA)'s trailing twelve month Return on Equity (ROE) is -99.74% as of 2026-06-30.
What is DMRA's ROA (return on assets)?
Damora Therapeutics, Inc. (DMRA)'s trailing twelve month Return on Assets (ROA) is -94.32% as of 2026-06-30.
What is DMRA's ROIC (return on invested capital)?
Damora Therapeutics, Inc. (DMRA)'s trailing twelve month Return on Invested Capital (ROIC) is -2976.03% as of 2025-12-31.
What is DMRA's EV/EBITDA?
Damora Therapeutics, Inc. (DMRA)'s trailing twelve month EV/EBITDA is -3.88x as of 2026-06-30.